Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Prospective Study Evaluating the Role of Personalized Chemotherapy Regimens for Chemo-Naive Select Stage IIIB and IV Non-Small Cell Lung Cancer (NSCLC) in Patients Using a Genomic Predictor of Platinum Resistance to Guide Therapy

NCT00509366 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT00509366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00509366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Prospective Study Evaluating the Role of Personalized Chemotherapy Regimens for Chemo-Naive Select Stage IIIB and IV Non-Small Cell Lung Cancer (NSCLC) in Patients Using a Genomic Predictor of Platinum Resistance to Guide Therapy
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2007
Completion date
December 31, 2011
Enrollment
101 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer